



**FULBRIGHT & JAWORSKI L.L.P.**

A REGISTERED LIMITED LIABILITY PARTNERSHIP  
600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701-3271  
WWW.FULBRIGHT.COM

STEVEN L. HIGHLANDER  
PARTNER  
SHIGHLANDER@FULBRIGHT.COM


DIRECT DIAL: (512) 536-3184  
TELEPHONE: (512) 474-5201  
FACSIMILE: (512) 536-4598

1646  
**RECEIVED**

AUG 22 2002

TECH CENTER 1600/2900

August 15, 2002

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on the date below:	
August 15, 2002	
Date	

Commissioner for Patents  
Washington, DC 20231

Re: *U.S. Patent Application No. 09/872,852 entitled "HUMAN BETA-DEFENSIN-3 (HBD-3), A HIGHLY CATIONIC BETA-DEFENSIN ANTIMICROBIAL PEPTIDE" by Paul B. McCray, Jr. et al.*  
*Our Reference: IOWA:031US*  
*Client Reference: UIRF:M0-49*


Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, Form PTO-1449, and references (A1, B5-B6).

No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/IOWA:031US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

  
Steven L. Highlander  
Reg. No. 37,642

SLH/cmb  
Encl.: as noted  
25197861.1



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Paul B. McCray, Jr. *et al.*

Serial No.: 09/872,852

Filed: June 1, 2001


For: HUMAN BETA-DEFENSIN-3 (HBD-3), A  
HIGHLY CATIONIC BETA-DEFENSIN  
ANTIMICROBIAL PEPTIDE

Group Art Unit: 1646

Examiner: Unknown

Atty. Dkt. No.: IOWA:031US

RECEIVED  
AUG 22 2002  
TECH CENTER 1600/2900

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
August 15, 2002	
Date	Steven L. Highlander

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
Washington, D.C. 20231

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/IOWA:031US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Steven P. Highlander  
Reg. No. 37,642  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: August 15, 2002

Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

IOWA:031US

Serial No.

09/872,852

Applicant

Paul B. McCray, Jr. *et al.*

Filing Date:

June 1, 2001

Group:

1646

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
<i>HR</i>	A1	6,399,370 B1	6/4/02	Wilson <i>et al.</i>	435	325	1/12/99

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B5	DE 10033505.5	7/1100	Germany			No
<i>HR</i>	B6	WO 02/04487	1/17/02	PCT			Yes, Abstract only

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

25197847.1


EXAMINER:

*Hope Robinson*

DATE CONSIDERED:

*10/30/03*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



## FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP  
600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701-3271  
WWW.FULBRIGHT.COM

STEVEN L. HIGHLANDER  
PARTNER  
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3184  
TELEPHONE: (512) 474-5201  
FACSIMILE: (512) 536-4598

July 24, 2002

RECEIVED

AUG 01 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
Date	July 24, 2002
	Steven L. Highlander

Commissioner for Patents  
Washington, DC 20231

Re: U.S. Patent Application No. 09/872,852 entitled "HUMAN BETA-DEFENSIN-3 (HBD-3), A HIGHLY CATIONIC BETA-DEFENSIN ANTIMICROBIAL PEPTIDE" by Paul B. McCray, Jr. et al.  
Our Reference: IOWA:031US  
Client Reference: UIRF:M0-49

Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, Form PTO-1449, and references (B1-B4).

No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/IOWA:031US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Steven L. Highlander  
Reg. No. 37,642

SLH/cmb  
Encl.: as noted  
25189868.1

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Paul B. McCray, Jr. *et al.*

Serial No.: 09/872,852

Filed: June 1, 2001

For: HUMAN BETA-DEFENSIN-3 (HBD-3), A  
HIGHLY CATIONIC BETA-DEFENSIN  
ANTIMICROBIAL PEPTIDE



Group Art Unit: 1646

Examiner: Unknown

Atty. Dkt. No.: IOWA:031US

RECEIVED

AUG 01 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below.	
July 24, 2002	
Date	Steven L. Highlander

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
Washington, D.C. 20231

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/IOWA:031US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Steven L. Highlander  
Reg. No. 37,642  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: July 24, 2002

Form PTO-1449 (modified)

Atty. Docket No.

IOWA:031US

Serial No.

09/872,852

List of Patents and Publications for Applicant's

Applicant

Paul B. McCray, Jr. *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

June 1, 2001

Group:

1646

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
✓	B1	WO 00/46245	8/10/00	PCT	—	—	
	B2	WO 02/04487	1/17/02	PCT	—	—	
	B3	WO 02/09738	2/7/02	PCT	—	—	
✓	B4	WO 99/13080	3/18/99	PCT	—	—	

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

RECEIVED  
AUG 01 2002  
TECH CENTER 1600/2900

25189853.1

EXAMINER:

Dope Robinson

DATE CONSIDERED:

10/30/03

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.





1646

TELEPHONE: 512/474-6201  
FACSIMILE: 512/536-3184  
STEVEN L. HIGHLANDER  
PARTNER  
INTERNET ADDRESS:  
SHIGHLANDER@FULBRIGHT.COM  
DIRECT DIAL: 512/536-3184

FULBRIGHT & JAWORSKI L.L.P.  
A REGISTERED LIMITED LIABILITY PARTNERSHIP  
600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701

HOUSTON  
WASHINGTON, D.C.  
AUSTIN  
SAN ANTONIO  
DALLAS  
NEW YORK  
LOS ANGELES  
MINNEAPOLIS  
LONDON  
HONG KONG

RECEIVED

APR 11 2002

April 4, 2002

TECH CENTER 1600/2900 FILE: IOWA:031US

CERTIFICATE OF MAILING 37 C.F.R. § 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
April 4, 2002	
Date	
	Steven L. Highlander

Commissioner for Patents  
Washington, DC 20231

RE: SN 09/872,852 "HUMAN BETA-DEFENSIN-3 (HBD-3), A HIGHLY CATIONIC BETA-DEFENSIN ANTIMICROBIAL PEPTIDE" - Paul B. McCray, Jr., et al. (Client Reference: URIF:M0-49)

Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, Form PTO-1449, and references (C15).

No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10104720/SLH.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Steven L. Highlander  
Reg. No. 37,642

SLH/cmb  
Encl: as noted



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

RECEIVED

In re Application of:

Paul B. McCray, Jr., *et al.*

Group Art Unit: 1646

APR 11 2002

Serial No.: 09/872,852

Examiner: Unknown

TECH CENTER 1600/2900

Filed: June 1, 2001

Atty. Dkt. No.: IOWA:031US/SLH

For: HUMAN BETA-DEFENSIN-3 (HBD-3), A  
HIGHLY CATIONIC BETA-DEFENSIN  
ANTIMICROBIAL PEPTIDE

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
April 4, 2002	
Date	Steven Highlander

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
Washington, D.C. 20231

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10104720/SLH.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,

  
Steven L. Highlander  
Reg. No. 37,642  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: April 4, 2002

Form PTO-1449 (modified)


Atty. Docket No.  
IOWA:031US/SLHSerial No.  
09/872,852

List of Patents and Publications for Applicant's

Applicant  
Paul B. McCray, Jr., *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:  
June 1, 2001Group:  
1646U.S. Patent Documents  
*See Page 1*Foreign Patent Documents  
*See Page 1*Other Art  
*See Page 1*

TECH CENTER 1600/2900

APR 11 2002

RECEIVED

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>HK</i>	C15	Co-pending U.S. Patent Application Serial Number 09/642,744 by Brian F. Tack <i>et al.</i> , filed August 18, 2000.

25151217.1

EXAMINER:

*Hope Robinson*

DATE CONSIDERED:

*10/30/03*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

TELEPHONE: 512/474-5272  
FACSIMILE: 512/536-3888  
STEVEN L. HIGHLANDER  
PARTNER  
INTERNET ADDRESS:  
SHIGHLANDER@FULBRIGHT.COM  
DIRECT DIAL: 512/536-3184

FULBRIGHT & JAWORSKI L.L.P.  
A REGISTERED LIMITED LIABILITY PARTNERSHIP  
600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701

GP/1646  
1653  
HOUSTON  
WASHINGTON, D.C.  
AUSTIN  
SAN ANTONIO  
DALLAS  
NEW YORK  
LOS ANGELES  
MINNEAPOLIS  
LONDON  
HONG KONG

RECEIVED

DEC 04 2001

October 29, 2001

TECH CENTER 1600/2900

FILE: IOWA:031US

CERTIFICATE OF MAILING 37 C.F.R 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
October 29, 2001	
Date	Steven L. Highlander

Commissioner for Patents  
Washington, DC 20231

RE: SN 09/872,852 "HUMAN BETA-DEFENSIN-3 (HBD-3), A HIGHLY CATIONIC BETA-DEFENSIN ANTIMICROBIAL PEPTIDE" - Paul B. McCray, Jr., et al. (Client Reference: URIF:MO-49)

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references (C1-C14).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10104720/SLH.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Steven L. Highlander  
Reg. No. 37,642

SLH/cmb

Encl: as noted



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In application of:

Paul B. McCray, Jr., *et al.*

Serial No.: 09/872,852

Filed: June 1, 2001

For: HUMAN BETA-DEFENSIN-3 (HBD-3), A  
HIGHLY CATIONIC BETA-DEFENSIN  
ANTIMICROBIAL PEPTIDE

Group Art Unit: 1646

Examiner: Unknown

Atty. Dkt. No.: IOWA:031US/SLH

#7 12/20/01  
Bray

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on the date below:	
October 29, 2001	
Date	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, D.C. 20231

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10104720/SLH.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Steven L. Highlander  
Reg. No. 37,642  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: October 29, 2001

Form PTO-1449 (modified)

Atty. Docket No.  
IOWA:031US/SLHSerial No.  
09/872,852

List of Patents and Publications for Applicant's

Applicant  
Paul B. McCray, Jr., *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:  
June 1, 2001Group:  
1646U.S. Patent Documents  
*See Page 1*Foreign Patent Documents  
*See Page 1*Other Art  
*See Page 1*

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<input checked="" type="checkbox"/>	C1	Gallo, <i>et al.</i> , "Antimicrobial peptides: an emerging concept in cutaneous biology," <i>J. Invest Dermatol</i> , 111(5):739-743, 1998.
<input type="checkbox"/>	C2	Ganz and Lehrer, "Antimicrobial peptides of vertebrates," <i>Current Opinions Immun</i> , 10:41-44, 1998.
<input type="checkbox"/>	C3	Hamil <i>et al.</i> , "HE2 $\beta$ and HE2 $\gamma$ , new members of an epididymis-specific family of androgen-regulated proteins in the human," <i>Endocrinology</i> , 141(3): 1245-1253, 2000.
<input type="checkbox"/>	C4	Harder <i>et al.</i> , "Short communication—Mapping of the gene encoding human $\beta$ -Defensin-2 (DEFB2) to chromosome region 8p22-p23.1," <i>Genomics</i> , 46:472-475, 1997.
<input type="checkbox"/>	C5	Jia <i>et al.</i> , "Discovery of new human $\beta$ -defensins using a genomics-based approach," <i>Gene</i> , 263:211-218, 2001.
<input type="checkbox"/>	C6	Kirchhoff <i>et al.</i> , "CD52 mRNA is modulated by androgens and temperature in epididymal cell cultures," <i>Mol. Reprod. Dev.</i> , 56:26-33, 2000.
<input type="checkbox"/>	C7	Krull <i>et al.</i> , "Region-specific variation of gene expression in the human epididymis as revealed by in situ hybridization with tissue-specific cDNAs," <i>Mol. Reprod. Dev.</i> , 34:16-24, 1993.
<input checked="" type="checkbox"/>	C8	Liu <i>et al.</i> , "Induction of apoptosis by thiuramdisulfides, the reactive metabolites of dithiocarbamates, through coordinative modulation of NF $\kappa$ B, c-fos/c-jun, and p53 proteins," <i>Mol. Carcinog.</i> , 22:235-246, 1998.

25066728.1

EXAMINER:

*Doyle Robinson*

DATE CONSIDERED:

*10/30/03*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



Form PTO-1449 (modified)

Atty. Docket No.  
IOWA:031US/SLHSerial No.  
09/872,852

List of Patents and Publications for Applicant's

Applicant  
Paul B. McCray, Jr., *et al.*

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:  
June 1, 2001Group:  
1646U.S. Patent Documents  
*See Page 1*Foreign Patent Documents  
*See Page 1*Other Art  
*See Page 1*

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>MR</i>	C9	Mathews <i>et al.</i> , "Production of $\beta$ -defensin antimicrobial peptides by the oral mucosa and salivary glands," <i>Infect Immun.</i> , 67(6):2740-2745, 1999.
	C10	Nilsson <i>et al.</i> , "Patient education for adults with chronic eczema," <i>Dermatol Nurs</i> , 11(2):117-122, 1999.
	C11	Oren and Shai, "Mode of action of linear amphipathic $\alpha$ -helical antimicrobial peptides," <i>Biopolymers</i> , 47:451-463, 1998.
	C12	Osterhoff <i>et al.</i> , "Molecular cloning and characterization of a novel human sperm antigen (HE2) specifically expressed in the proximal epididymis," <i>Biol Reprod</i> , 50:516-525, 1994.
	C13	Russell <i>et al.</i> , "Coordinate induction of two antibiotic genes in tracheal epithelial cells exposed to the inflammatory mediators lipopolysaccharide and tumor necrosis factor alpha," <i>Infect Immun.</i> , 64(5):1565-1568, 1996.
<i>✓</i>	C14	Singh <i>et al.</i> , "Production of $\beta$ -defensins by human airway epithelia," <i>Proc. Natl. Acad. Sci USA.</i> , 95:14961-14966, 1998.

25066728.1

EXAMINER:

*Aoze Robinson*

DATE CONSIDERED:

*10/30/03*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.